UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
|
___________________
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934
For the month of May 2016
Commission File Number: 001-32001
___________________
Aptose Biosciences Inc. (Translation of registrant's name into English)
5955 Airport Road, Suite 228 Canada ___________________
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-FR Form 40-F £
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1) £
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7) £
|
INCORPORATION BY REFERENCE
Exhibits 99.1 and 99.2 to this Report of Foreign Issuer on Form 6-K of Aptose Biosciences Inc. (the “Registrant”) are each hereby incorporated by reference into the registration statement on Form F-3 of the Registrant (File No. 333-200660) and the prospectus, forming a part thereof.
DOCUMENTS FILED AS PART OF THIS FORM 6-K
See Exhibit Index hereto.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| Aptose Biosciences Inc. | |||
| Date: May 10, 2016 | By: | “Gregory Chow” | |
| Name: | Gregory Chow | ||
| Title: | Senior Vice President and Chief Financial Officer | ||
EXHIBIT INDEX
| 99.1 | Interim Financial Statements | |
| 99.2 | Management’s Discussion and Analysis | |
| 99.3 | CEO and CFO Certificates |